0001144204-18-034065.txt : 20180613
0001144204-18-034065.hdr.sgml : 20180613
20180613163226
ACCESSION NUMBER: 0001144204-18-034065
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180607
FILED AS OF DATE: 20180613
DATE AS OF CHANGE: 20180613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wirostko Barbara
CENTRAL INDEX KEY: 0001669087
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36672
FILM NUMBER: 18897055
MAIL ADDRESS:
STREET 1: C/O EYEGATE PHARMACEUTICALS, INC.
STREET 2: 271 WAVERLY OAKS ROAD, SUITE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001372514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 271 WAVERLEY OAKS ROAD
STREET 2: SUITE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
BUSINESS PHONE: 781-788-9043
MAIL ADDRESS:
STREET 1: 271 WAVERLEY OAKS ROAD
STREET 2: SUITE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
4/A
1
tv496443_4a.xml
OWNERSHIP DOCUMENT
X0306
4/A
2018-06-07
2018-06-11
0
0001372514
EYEGATE PHARMACEUTICALS INC
EYEG
0001669087
Wirostko Barbara
C/O EYEGATE PHARMACEUTICALS, INC.
271 WAVERLY OAKS ROAD, SUITE 108
WALTHAM
MA
02452
0
1
0
0
Chief Medical Officer
Common Stock
2018-06-07
4
A
0
2215
0.52
A
52915
I
By husband
Common Stock
2018-06-07
4
A
0
9600
0.52
A
249997
D
Common Stock
2018-06-08
4
A
0
7000
0.54
A
59915
I
By husband
The Form 4 previously filed on June 11, 2018 inadvertently misclassified the 2,215 shares purchased on June 7, 2018 and 7,000 shares purchased on June 8, 2018 as being beneficially owned directly by the reporting person instead of indirectly, and inadvertently omitted the purchase of 9,600 shares by the reporting person on June 7, 2018, which are beneficially owned directly. This amendment corrects that error to add the omitted transaction from June 7, 2018 and to reflect the correct number of shares beneficially owned by the reporting person, both directly and indirectly, after the reported transaction.
/s/ Robert A. Petitt, attorney-in-fact
2018-06-13